AstraZeneca Results Presentation Deck
19
Oncology: R&D pipeline highlights
Positive data in liver cancer and biliary tract cancer
Imfinzi + treme HIMALAYA
1st-line liver cancer
• Combination met primary endpoint of
improved overall survival versus
sorafenib
●
• Positive data for STRIDE (Single
Tremelimumab Regular Interval
Durvalumab) regimen
• Favourable safety profile
US FDA
ODD
received
STRIDE = Single Tremelimumab Regular Interval Durvalumab.
Imfinzi TOPAZ-1
+ chemo in 1st-line biliary tract cancer
• Met primary endpoint of improved
overall survival versus standard of care
chemotherapy
• Improvement also seen in progression-
free survival and overall response rate
Strong safety profile
New prospects for immuno-oncology franchise
in gastrointestinal cancers
US FDA
ODD
receivedView entire presentation